Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

661 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
Steinberg BA, Kim S, Thomas L, Fonarow GC, Hylek E, Ansell J, Go AS, Chang P, Kowey P, Gersh BJ, Mahaffey KW, Singer DE, Piccini JP, Peterson ED; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Steinberg BA, et al. Among authors: mahaffey kw. Circulation. 2014 May 20;129(20):2005-12. doi: 10.1161/CIRCULATIONAHA.114.008643. Epub 2014 Mar 29. Circulation. 2014. PMID: 24682387 Free PMC article.
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, Armstrong PW; COMPLY Investigators. Mahaffey KW, et al. Circulation. 2003 Sep 9;108(10):1176-83. doi: 10.1161/01.CIR.0000087404.53661.F8. Epub 2003 Aug 18. Circulation. 2003. PMID: 12925455 Clinical Trial.
Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.
Singh KP, Roe MT, Peterson ED, Chen AY, Mahaffey KW, Goodman SG, Harrington RA, Smith SC Jr, Gibler WB, Ohman EM, Pollack CV Jr; CRUSADE Investigators. Singh KP, et al. Among authors: mahaffey kw. J Thromb Thrombolysis. 2006 Jun;21(3):211-20. doi: 10.1007/s11239-006-5708-0. J Thromb Thrombolysis. 2006. PMID: 16683212 Clinical Trial.
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
Tricoci P, Lokhnygina Y, Berdan LG, Steinhubl SR, Gulba DC, White HD, Kleiman NS, Aylward PE, Langer A, Califf RM, Ferguson JJ, Antman EM, Newby LK, Harrington RA, Goodman SG, Mahaffey KW. Tricoci P, et al. Among authors: mahaffey kw. Circulation. 2007 Dec 4;116(23):2669-77. doi: 10.1161/CIRCULATIONAHA.107.690081. Epub 2007 Nov 19. Circulation. 2007. PMID: 18025532
Rivaroxaban, an oral direct factor Xa inhibitor.
Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM. Piccini JP, et al. Among authors: mahaffey kw. Expert Opin Investig Drugs. 2008 Jun;17(6):925-37. doi: 10.1517/13543784.17.6.925. Expert Opin Investig Drugs. 2008. PMID: 18491993 Review.
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV).
Yau JM, Alexander JH, Hafley G, Mahaffey KW, Mack MJ, Kouchoukos N, Goyal A, Peterson ED, Gibson CM, Califf RM, Harrington RA, Ferguson TB; PREVENT IV Investigators. Yau JM, et al. Among authors: mahaffey kw. Am J Cardiol. 2008 Sep 1;102(5):546-51. doi: 10.1016/j.amjcard.2008.04.069. Epub 2008 Jul 2. Am J Cardiol. 2008. PMID: 18721510 Clinical Trial.
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
APPRAISE Steering Committee and Investigators; Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L. APPRAISE Steering Committee and Investigators, et al. Circulation. 2009 Jun 9;119(22):2877-85. doi: 10.1161/CIRCULATIONAHA.108.832139. Epub 2009 May 26. Circulation. 2009. PMID: 19470889 Clinical Trial.
Influence of clinical trial participation on subsequent antithrombin use.
Shah BR, Peterson ED, Chen AY, Mahaffey KW, DeLong ER, Ohman EM, Pollack CV Jr, Gibler WB, Roe MT. Shah BR, et al. Among authors: mahaffey kw. Clin Cardiol. 2010 Mar;33(3):E49-55. doi: 10.1002/clc.20581. Clin Cardiol. 2010. PMID: 20127904 Free PMC article.
661 results